Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Targeted Intra-arterial Gemcitabine vs. Continuation of IV Gemcitabine Plus Nab-Paclitaxel Following Induction With Sequential IV Gemcitabine Plus Nab-Paclitaxel and Radiotherapy for Locally Advanced Pancreatic Cancer

NCT03257033 is registered in ClinicalTrials.gov with RenovoRx as lead sponsor.

NCT NCT03257033
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03257033 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Targeted Intra-arterial Gemcitabine vs. Continuation of IV Gemcitabine Plus Nab-Paclitaxel Following Induction With Sequential IV Gemcitabine Plus Nab-Paclitaxel and Radiotherapy for Locally Advanced Pancreatic Cancer
Lead sponsor
RenovoRx
Phase
Phase 3
Overall status
Active, not recruiting
Start date
March 12, 2018
Completion date
September 30, 2027
Enrollment
190 (estimated)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced pancreatic cancer